C OSBORNE to Drug Administration Schedule
This is a "connection" page, showing publications C OSBORNE has written about Drug Administration Schedule.
Connection Strength
0.154
-
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol. 1997 Jul; 15(7):2494-501.
Score: 0.025
-
Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1996 Jan; 14(1):46-51.
Score: 0.022
-
Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol. 1994 Jan; 5(1):43-7.
Score: 0.019
-
A Southwest Oncology Group phase II Trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991 Oct 15; 68(8):1694-5.
Score: 0.016
-
Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 2007 Apr; 30(2):113-25.
Score: 0.012
-
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol. 2007 Feb 20; 25(6):656-61.
Score: 0.012
-
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 01; 23(25):5973-82.
Score: 0.011
-
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005 Apr 10; 23(11):2460-8.
Score: 0.010
-
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
Score: 0.009
-
Combined chemo-hormonal therapy in breast cancer: a hypothesis. Breast Cancer Res Treat. 1981; 1(2):121-3.
Score: 0.008
-
Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study. J Clin Oncol. 1998 Jul; 16(7):2382-91.
Score: 0.007
-
Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. N Engl J Med. 1989 Feb 23; 320(8):485-90.
Score: 0.003